$12.49
1.46% yesterday
NYSE, Dec 24, 08:48 pm CET
ISIN
US03237H1014
Symbol
AMLX

Amylyx Pharmaceuticals Stock price

$12.49
-2.33 15.72% 1M
+6.08 94.85% 6M
+8.71 230.42% YTD
+8.49 212.25% 1Y
-23.07 64.88% 3Y
-5.58 30.88% 5Y
-5.58 30.88% 10Y
-5.58 30.88% 20Y
NYSE, Closing price Wed, Dec 24 2025
+0.18 1.46%
ISIN
US03237H1014
Symbol
AMLX
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.0b
Net debt
positive
Cash
$344.0m
Shares outstanding
109.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.1
Financial Health
Equity Ratio
85.1%
Return on Equity
-183.1%
ROCE
-46.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-156.8m | $-161.1m
EBIT
$-157.3m | $-161.2m
Net Income
$-149.3m | $-176.5m
Free Cash Flow
$-154.5m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
-31.1% | 0.7%
EBIT
-30.5% | 1.2%
Net Income
42.5% | 41.5%
Free Cash Flow
-17.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.4
Short interest
11.5%
Employees
123
Rev per Employee
$710.0k
Show more

Is Amylyx Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Amylyx Pharmaceuticals forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy
88%
Hold
12%

Financial data from Amylyx Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 65 65
57% 57%
-
- Research and Development Expense 92 92
27% 27%
-
-157 -157
31% 31%
-
- Depreciation and Amortization 0.58 0.58
45% 45%
-
EBIT (Operating Income) EBIT -157 -157
30% 30%
-
Net Profit -149 -149
42% 42%
-

In millions USD.

Don't miss a Thing! We will send you all news about Amylyx Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amylyx Pharmaceuticals Stock News

Positive
The Motley Fool
16 days ago
Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter.
Neutral
Business Wire
20 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial.
Neutral
Seeking Alpha
22 days ago
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Josh Klee
Employees 123
Founded 2013
Website www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today